These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35136832)

  • 1. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis.
    Khater I; Nassar A
    Inform Med Unlocked; 2022; 29():100873. PubMed ID: 35136832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
    Ibrahim IM; Elfiky AA; Elgohary AM
    Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors.
    Sarma S; Herrera SM; Xiao X; Hudalla GA; Hall CK
    J Phys Chem B; 2022 Oct; 126(41):8129-8139. PubMed ID: 36219223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
    Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive treatment of coronavirus disease-2019 virus using coronavirus disease-2019-receptor-binding domain 1C aptamer by suppress the expression of angiotensin-converting enzyme 2 receptor.
    Hameed NS; Arif IS; Al-Sudani BT
    J Adv Pharm Technol Res; 2023; 14(3):185-190. PubMed ID: 37692001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots.
    Pramanik A; Sharma PC; Patibandla S; Gao Y; Ruppa-Kasani V; Goli J; Kumar A; Chatterjee A; Sinha SS; Bates JT; Bierdeman MA; Tandon R; Ray PC
    ACS Omega; 2022 Mar; 7(9):8150-8157. PubMed ID: 35252734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity.
    Liu H; Wei P; Aviszus K; Zhang Q; Linderberger J; Yang J; Liu J; Chen Z; Waheed H; Reynoso L; Downey GP; Frankel SK; Kappler JW; Marrack P; Zhang G
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
    Borkotoky S; Dey D; Hazarika Z
    Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Cysteine Oxidation in SARS-CoV-2 Receptor-Binding Domain on Its Interaction with Two Cell Receptors: Insights from Atomistic Simulations.
    Ghasemitarei M; Privat-Maldonado A; Yusupov M; Rahnama S; Bogaerts A; Ejtehadi MR
    J Chem Inf Model; 2022 Jan; 62(1):129-141. PubMed ID: 34965734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.